Priya Singhal
CIK 1769608 · Head of Development · last filed 2026-02-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.70M
Companies
2
Total Filings
28
Lifetime Open-Market Net
-$2.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIIB | Head of Development | 8,488 | $200.05 | $1.70M | -$2.02M | 27 | 2026-02-17 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Head of Research & Development | — | — | — | $0 | 1 | 2019-04-04 |
Recent Filings · Page 2 of 3
28 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-04-03 | BIIB | Sell (S) | −93 | -$19.8K | EDGAR |
| 2024-02-26 | BIIB | Sell (S) | −262 | -$58.0K | EDGAR |
| 2024-02-21 | BIIB | Mixed | +632 | -$126.5K | EDGAR |
| 2024-02-13 | BIIB | Mixed | +419 | -$190.5K | EDGAR |
| 2024-02-09 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2024-02-05 | BIIB | Mixed | +633 | -$295.0K | EDGAR |
| 2024-01-31 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2023-12-12 | BIIB | Mixed | +110 | -$76.6K | EDGAR |
| 2023-09-06 | BIIB | Mixed | +430 | -$331.7K | EDGAR |
| 2023-07-05 | BIIB | Mixed | +81 | -$66.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.